Last updated 42 hours ago

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

1000 patients around the world

Available in Brazil, Puerto Rico, United States

Eli Lilly and Company

7Research sites

1000Patients around the world

This study is for people with

Obesity

Diabetes

Diabetes mellitus type 2

From 18 Years

All Gender

: Have type 2 diabetes.
Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening.
Have a BMI of ≥27 kg/m2 at screening.
Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.

: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening).
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening).
Have type 1 diabetes.
Have taken any of the following within 90 days prior to screening.
Medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies.
Dipeptidyl peptidase 4 (DPP-4) inhibitors, and.
Insulin.
Have had within 90 days prior to screening.
Heart attack.
Stroke.
Coronary artery revascularization.
Unstable angina, or.
Hospitalization due to congestive heart failure.
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.
Have taken medications or alternative remedies intended for weight loss within 90 days of screening.

Centro Paulista de Investigação Clínica - CEPIC

R. Moreira e Costa, 342 - Ipiranga, São Paulo - SP, 04266-010

Cline Research Center

Praça São Paulo da Cruz, 50 - Cabral, Curitiba - PR, 80030-000

Núcleo de Pesquisa Clínica do Rio Grande do Sul - NPCRS

Rua Mostardeiro 5/310, Porto Alegre, Rio Grande do Sul

Centro de Pesquisa Sao Lucas

Campinas, Sao Paulo

CPClin – Centro de Pesquisas Clinicas LTDA

Avenida Angélica, 2162 – Consolação – São Paulo, SP, CEP:01228-200

Instituto Brasil de Pesquisa Clínica - IBPClin

R. da Glória, 344 - Glória, Rio de Janeiro - RJ, 20241-180

Latin Clinical Trial Center - Puerto Rico

1801 Av. Juan Ponce de León, San Juan, 00926, Puerto Rico

StudyAMPLIFY-2

SponsorEli Lilly and Company

Study typeInterventional

Conditions

ObesityDiabetes mellitus type 2

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07881458